Cambridge, Mass.– Enveric Biosciences has been granted a new U.S. patent covering a unique family of molecules designed to target the melatonin receptor system, opening new possibilities for the development of therapies aimed at treating sleep and central nervous system (CNS) disorders.
The patent (U.S. Patent No. 12,187,679), titled “Hydroxylated Psilocybin Derivatives and Methods of Using,” includes a structurally diverse class of small molecules discovered through Enveric’s proprietary drug screening and design platform. Several of these compounds selectively bind to the melatonin MT1 receptor, a validated target known to regulate circadian rhythms and sleep-wake cycles.
The announcement strengthens Enveric’s intellectual property portfolio and supports its broader strategy of developing neuroplastogenic small-molecule therapeutics to address psychiatric and neurological conditions.
Melatonin signaling has been widely recognized in the treatment of sleep and mood disorders. Approved therapies such as ramelteon (Rozerem®) and agomelatine (Valdoxan®) demonstrate the effectiveness of targeting MT1 and MT2 receptors for insomnia and major depressive disorder. Enveric’s newly patented compounds may offer a next-generation alternative by exhibiting MT1-selective agonist activity and potentially broader receptor engagement, positioning them as candidates for treating complex CNS disorders.
“This newly issued patent adds to the growing body of intellectual property that underpins our pipeline of next-generation neuroplastogenic therapeutics,” said Dr. Joseph Tucker, CEO of Enveric Biosciences. “The inclusion of melatonin receptor-binding compounds expands our therapeutic reach into sleep disorders—a major area of unmet need with a market valued in the billions annually. This milestone enhances our ability to develop differentiated therapies where current treatments fall short.”
Enveric plans to continue leveraging its drug discovery capabilities to develop novel treatments that combine receptor specificity with broader CNS activity, aiming to address both common and treatment-resistant conditions in psychiatry and neurology.
